The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial

Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for solid tumors. However, even in cancers generally considered ICI-sensitive, responses can vary significantly. Thus, there is an ever-increasing interest in identifying novel means of improving therapeutic responses, both...

Descripción completa

Detalles Bibliográficos
Autores principales: Metropulos, Anastasia E., Munshi, Hidayatullah G., Principe, Daniel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706619/
https://www.ncbi.nlm.nih.gov/pubmed/36455409
http://dx.doi.org/10.1016/j.ebiom.2022.104380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706619/
https://www.ncbi.nlm.nih.gov/pubmed/36455409
http://dx.doi.org/10.1016/j.ebiom.2022.104380

Ejemplares similares